SYK

As of 2026-09-10, SYK scores 45out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. SYK trades at $270.01, within its fair-value band.

SYK scores 45 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 45. Its strongest factor is value at 74 (strong), where it screens cheap on the model's valuation inputs, followed by quality at 56. The weakest is momentum at 16, where price trend is the soft spot. Among Healthcare stocks it sits in the lower 46% of Healthcare names by composite.

On valuation, SYK is priced around the middle of its recent range. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 47. Same-sector names the model rates nearby include HALO, THC, TGTX.

This is a descriptive factor read on SYK, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where SYK sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for SYK runs $230.80–$331.26. Current price $270.01 sits within its fair-value band. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-09-10.